Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease
The DOI matches its Crossref record.
Abstract
P-glycoprotein is a membrane protein encoded by theMDR1gene, which demonstrates functional polymorphism. It is present in endothelial cells of the blood-brain barrier, thus limiting accumulation of its substrates in the central nervous system. Many epidemiological studies suggest an association between pesticides, which are substrates for P-glycoprotein, and Parkinson's disease. It was hypothesized that polymorphism of theMDR1gene could modulate interindividual susceptibility for the disease in subjects exposed to pesticides. In a pilot case-control study involving 107 Parkinson's disease patients (30 early onset and 77 late onset patients; 59 exposed to pesticides and 48 non-exposed) and 103 controls, C3435T polymorphism of the gene was analysed. No statistically significant correlation betweenMDR1gene polymorphism and Parkinson's disease was found. The 3435TT genotype was noted more frequently, but not significantly, in patients with early onset compared to late onset disease (23.3% versus 10.4%, respectively). A significant association between patients with parkinsonism exposed to pesticides and C3435T polymorphism of theMDR1gene was found. Comparing the exposed and non-exposed patients, a statistically higher frequency of heterozygous subjects was observed (72.9% versus 47.9%, respectively). This genotype was associated with a significant, almost three-fold increased risk of disease. Similarly, a higher frequency of 3435TT subjects was revealed in exposed subjects (15.5%) compared to non-exposed patients (12.5%). In exposed versus non-exposed subjects, patients carrying at least one 3435T allele (i.e. homozygous and heterozygous) had a significant, five-fold higher risk of Parkinson's disease. Thus, it appears that mutation of the MDR1 gene predisposes to damaging effects of pesticides, and possibly other toxic xenobiotics transported by P-glycoprotein, leading to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 17
- Markopoulou, 1999, Neurology, 53, 1382, 10.1212/WNL.53.7.1382 · doi:10.1212/wnl.53.7.1382
- Tan, 2000, Neurology, 55, 533, 10.1212/WNL.55.4.533 · DOI · Paper page
- Bialecka, 2002, Eur J Clin Pharmacol, 57, 857, 10.1007/s00228-001-0415-4 · DOI
- De Palma, 1998, Lancet, 352, 1986, 10.1016/S0140-6736(05)61332-3 · doi:10.1016/s0140-6736(05)61332-3
- Gorell, 1998, Neurology, 50, 1346, 10.1212/WNL.50.5.1346 · DOI · Paper page
- Liou, 1997, Neurology, 48, 1583, 10.1212/WNL.48.6.1583 · DOI · Paper page
- Schinkel, 1994, Cell, 77, 491, 10.1016/0092-8674(94)90212-7 · DOI · Paper page
- Lankas, 1997, Toxicol Appl Pharmacol, 143, 357, 10.1006/taap.1996.8086 · DOI · Paper page
- Tanigawara, 2000, Ther Drug Monit, 22, 137, 10.1097/00007691-200002000-00029 · DOI · Paper page
- Schinkel, 1996, J Clin Invest, 97, 2517, 10.1172/JCI118699 · DOI · Paper page
- Hoffmeyer, 2000, Proc Natl Acad Sci USA, 97, 3473, 10.1073/pnas.97.7.3473 · DOI · Paper page
- Furuno, 2002, Pharmacogenetics, 12, 529, 10.1097/00008571-200210000-00004 · DOI · Paper page
- Hoehn, 1967, Neurology, 17, 427, 10.1212/WNL.17.5.427 · DOI · Paper page
- Cascorbi, 2001, Clin Pharmacol Ther, 69, 169, 10.1067/mcp.2001.114164 · DOI · Paper page
- Tanabe, 2001, J Pharmacol Exp Ther, 297, 1137
- Le Couteur, 2001, Eur Neurol, 45, 289, 10.1159/000052148 · DOI
- Schaeffler, 2001, Lancet, 358, 383, 10.1016/S0140-6736(01)05579-9 · DOI
Cited by
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
The blood–brain barrier in health and disease
Daneman, R. (2012) · Annals of Neurology · doi:10.1002/ana.23648 · Cited by 754
Metadata
- Authors
- Dro??dzik, M., Bia??ecka, M., My??liwiec, K., Honczarenko, K., Stankiewicz, J., & Sych, Z.
- Venue
- Pharmacogenetics
- Published
- 2003-05
- Volume
- 13
- Issue
- 5
- Pages
- 259-263
- ISSN
- 0960-314X (ISSN-L)
- OpenAlex
- W4249152566
- Cited by
- 143
- References
- 0
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. https://app.cochat.ai/papers/10.1097/00008571-200305000-00004
- The paper
- Dro??dzik, M., Bia??ecka, M., My??liwiec, K., Honczarenko, K., Stankiewicz, J., & Sych, Z. (2003). Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. https://doi.org/10.1097/00008571-200305000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.